Among adults with relapsed or refractory indolent B-cell non-Hodgkin lymphoma, the phase 2 TRANSCEND FL trial met its primary ...

Ciltacabtagene autoleucel (cilta-cel) is an FDA-approved anti–B-cell maturation ... of CAR T-cell therapy. An additional case of indolent CD4+ cytotoxic CAR+ T-cell lymphoma in the small ...

Despite research showing the benefits of circulating tumor DNA as an indicator of disease remission in B-cell lymphoma ... is the first step toward a cure in treating aggressive B-cell lymphomas ...

China's National Medical Products Administration has approved a Phase III trial of InnoCare Pharma’s ICP-248 (Mesutoclax) ...

We think the strategy to find more effective combination therapies in hematology and build a larger oncology and dermatology portfolio is solid, although we're waiting for key data before assuming the ...

Imbruvica (ibrutinib) is a Bruton’s tyrosine kinase (BTK) inhibitor approved for the treatment of Small Lymphocytic Lymphoma (SLL). It works by blocking BTK, a critical enzyme in B-cell receptor ...

After the pathogen has been eradicated, most involved immune cells die a programmed cell death, and the immune response is down-regulated in an orderly fashion, leaving only a small number of ...

In their effort to answer a decades-old biological question about how the hepatitis B virus (HBV) is able to establish infection of liver cells, research led by Memorial Sloan Kettering Cancer Center ...

Brice and Amanda Dieter of Jamestown had their figurative worlds upended in October 2023. It was at this time that the ...

Objective: The worldwide incidence of primary small intestinal lymphoma (PSIL ... The median age of onset was 58.5 years (range: 19-80 years). Diffuse large B-cell lymphoma (n=37) was the most common ...